Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

NCT02445053 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT02445053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02445053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Observational
Overall status
Completed
Start date
April 30, 2015
Completion date
October 31, 2020
Enrollment
75 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis